Get the Stockscreener App
4.24
0.00%
0.00
After Hours:
4.24
Savara Inc stock is traded at $4.24, with a volume of 905.82K.
It is up +0.00% in the last 24 hours and down -0.70% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$4.24
Open:
$4.26
24h Volume:
905.82K
Relative Volume:
0.68
Market Cap:
$700.38M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-15.14
EPS:
-0.28
Net Cash Flow:
$-51.36M
1W Performance:
-8.03%
1M Performance:
-0.70%
6M Performance:
-14.86%
1Y Performance:
+12.17%
1-Day Range:
$4.20
$4.315
1-Week Range:
$4.08
$4.665
52-Week Range:
$3.115
$5.70
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Inc. Appoints Braden Parker as Chief Commercial Officer - MyChesCo
What is Savara Inc (SVRA) Stock Return on Shareholders’ Capital? - SETE News
Savara's SWOT analysis: molgramostim's promise lifts rare disease stock By Investing.com - Investing.com UK
Frazier Life Sciences Management L.P. Raises Stock Position in Savara Inc (NASDAQ:SVRA) - MarketBeat
Savara Announces New Employment Inducement Grant - StockTitan
Savara launches early access program for aPAP treatment By Investing.com - Investing.com South Africa
Savara launches early access program for aPAP treatment - Investing.com
Savara launches early access program for aPAP treatment - Investing.com India
Savara Announces New Employment Inducement Grant - Business Wire
Savara launches early access program for aPAP treatment By Investing.com - Investing.com Canada
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - StockTitan
Analytical Overview: Savara Inc (SVRA)’s Ratios Tell a Financial Story - The Dwinnex
Savara Inc (SVRA) Stock: A Year of Decreases and Increases - The InvestChronicle
Affinity Asset Advisors LLC Acquires 396,850 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Taking on analysts’ expectations and winning: Savara Inc (SVRA) - SETE News
Savara appoints Braden Parker as Chief Commercial Officer - Investing.com India
What is the investor’s view on Savara Inc (SVRA)? - US Post News
Savara appoints Braden Parker as Chief Commercial Officer - Investing.com
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately - StockTitan
First Light Asset Management LLC Acquires Shares of 2,002,219 Savara Inc (NASDAQ:SVRA) - MarketBeat
Savara Inc (NASDAQ:SVRA) Receives Average Rating of "Buy" from Analysts - MarketBeat
Savara to Host Analyst and Investor Webinar on September 30, 2024 - StockTitan
Savara Inc (NASDAQ:SVRA) Given Average Rating of “Buy” by Brokerages - Defense World
Victory Capital Management Inc. Makes New $527,000 Investment in Savara Inc (NASDAQ:SVRA) - Defense World
Victory Capital Management Inc. Acquires Shares of 130,830 Savara Inc (NASDAQ:SVRA) - MarketBeat
Choreo LLC Makes New $59,000 Investment in Savara Inc (NASDAQ:SVRA) - Defense World
Bank of New York Mellon Corp Has $1.16 Million Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Principal Financial Group Inc. Increases Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Is Savara Inc (SVRA) a good investment opportunity? - US Post News
Savara (NASDAQ:SVRA) Stock Price Up 6% - MarketBeat
Savara Inc (SVRA) looking to reclaim success with recent performance - SETE News
Market Update: Savara Inc (SVRA) Sees Negative Movement, Closing at 4.20 - The Dwinnex
Savara Inc. Grants Inducement Awards to New Employee - MSN
A stock that deserves closer examination: Savara Inc (SVRA) - US Post News
Savara Inc’s Market Journey: Closing Strong at 4.40, Up 3.29 - The Dwinnex
Savara Inc. Grants Inducement Awards to New Employee - MyChesCo
Savara Inc (NASDAQ:SVRA) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Savara’s (SVRA) Market Outperform Rating Reaffirmed at JMP Securities - Defense World
Savara: Trial Successful, But I'm Only Half Convinced (NASDAQ:SVRA) - Seeking Alpha
Savara (NASDAQ:SVRA) Rating Reiterated by JMP Securities - MarketBeat
Boeing, crypto-exposed stocks, Savara surge premarket By Investing.com - Investing.com Canada
Boeing, crypto-exposed stocks, Savara surge premarket By Investing.com - Investing.com UK
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congres - Business Wire
Savara Inc (SVRA)’s stock chart: A technical perspective - US Post News
Savara Inc (SVRA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Savara (NASDAQ:SVRA) Stock Price Up 4.8% - MarketBeat
SVRASavara Inc. Latest Stock News & Market Updates - StockTitan
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? - Insider Monkey
Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? - Yahoo Finance
Savara Inc (NASDAQ:SVRA) Receives $11.17 Consensus Target Price from Analysts - MarketBeat
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):